Xigen S.A. Closes Its Series A Financing Round With CHF 26 Million
10/19/2005 5:09:12 PM
LAUSANNE, Switzerland--(BUSINESS WIRE)--Sept. 6, 2005--Xigen S.A., a Swiss biotechnology company engaged in research and development of intracellular peptide therapeutics for the treatment of stroke, myocardial infarction and cancer, announced today the successful conclusion of its Swiss Francs 26m (21m USD) Series A financing round with Tilocor Life Sciences, Venture Incubator (VI) and Initiative Capital (IC) as investors.
comments powered by